Open access peer-reviewed chapter - ONLINE FIRST

The Role of Anti-IgE Antibodies in Urticaria

By Patrizia Pepe and Victor Desmond Mandel

Submitted: December 15th 2020Reviewed: March 4th 2021Published: August 9th 2021

DOI: 10.5772/intechopen.97025

Downloaded: 37


Chronic urticaria, a common mast cell driven disease, has been considered so far an underestimated and difficult to treat disease, very often resulting in high physical, psychological and socio-economic burden. More than 60% of these patients are unresponsive to second generation H1 antihistamines, the first-line symptomatic treatment for urticaria. However, anti-IgE drugs (omalizumab and ligelizumab) showed improved activity in urticaria-treated patients with inadequate symptom control. Omalizumab has been widely proven to be very effective and well-tolerated in patients with antihistamine-refractory chronic spontaneous urticaria and inducible urticaria and is currently licensed for these indication as third-line treatment. Ligelizumab, a next-generation monoclonal anti-IgE antibody with higher affinity to IgE compared to omalizumab and a similar safety profile, has recently demonstrated to be even more effective than omalizumab. This review is focused on the role of anti-IgE antibodies in chronic urticaria.


  • Urticaria
  • Chronic Spontaneous Urticaria
  • Chronic Inducible Urticaria
  • Anti-IgE antibodies
  • Omalizumab
  • Ligelizumab

1. Introduction

Urticaria is a common mast cell-driven disease characterised by wheals (1–24 hours) and/or angioedema (up to 72 hours) (Figure 1), defined as acute when symptoms last <6 weeks or chronic if they occur continuously or intermittently for ≥6 weeks [1]. Approximately 50% of patients have both hives and angioedema, whereas 40% have wheals alone, and 10% have angioedema alone [2]. Moreover, Chronic Urticaria (CU) can be further classified as Chronic Inducible Urticaria (CIndU) when appear in response to specific eliciting factors, such as thermal agents, vibration, cholinergic factors, aquagenic, and delayed pressure or as Chronic Spontaneous Urticaria (CSU) if the above mentioned triggers have been excluded [1].

Figure 1.

(a–h): Urticaria is characterised by an outbreak of swollen, pale red bumps or plaques on the skin (wheals) and can also manifest as deep swelling around the eyes, lips, and face (angioedema) that appears suddenly.

1.1 The prevalence of Chronic Urticaria

Both children and adults may develop urticaria, with the peak age of onset in adults being between 20 and 40 years [2]. The lifetime prevalence of Acute Urticaria (AU) ranges from <1% to 24% (12% to 24% in Europe), depending on the age range, method of sampling, and geographic location [3]. Instead, CU is estimated at 1% but there is no reliable data regarding its prevalence due to the lack of cross-sectional studies [4]. About 20% to 45% of patients with AU develop into CU.

CSU occurs in 0.5–1% of the population at any point in time, with its incidence peaking between 20 and 40 years of age [5]. CSU is considered more common in adults than in children and women are affected twice as often as men. However, recent studies have suggested that the prevalence of CSU in the paediatric population is similar to that of the adult population [6].

Finally, the CIndU prevalence is lower than other types of urticaria (e.g., acquired cold urticaria in Europe is extimated around 0.5%) [3].

1.2 The burden of Chronic Urticaria

In 1997 O’Donnel et al. compared the Quality of Life (QoL) scores in 142 patients with CU and 98 patients with life-threatening heart disease, finding similar QoL scores in both groups [7]. Indeed, many CU patients exhibit a severe impairment of their quality of life. The long disease duration (on average aorund two to five years) and the lack of curative therapy have been underlined as the two main aspects that contribute to the high physical, psychological and socio-economic burden of CU [8, 9]. The last EAACI/GA2LEN/EDF/WAO guideline recommends “aiming at complete symptom control in urticaria, considering as much as possible the safety and the QoL of each individual patient” [1]. Currently, two specific QoL questionnaires are available for evaluating the burden of CU on patients: Chronic Urticaria Quality of Life (CU-Q2oL) and Angioedema Quality of Life (AE-QoL). Moreover, in order to collect quality, real-life data on CU patient characteristics, the course of disease, underlying causes, comorbidities, treatment responses, quality of life impairment and health care costs the Chronic Urticaria Registry was recently set up [10].

1.3 Patient-reported outcome measures in Chronic Urticaria

Patient-reported outcome measures are instruments of objective and subjective evaluation for the management of CU and are essential tools for assessing treatment effects in clinical trials.

As described above, CU-Q2oL and AE-QoL are the two questionnaires available for evaluating the CU burden on QoL. Instead, the Urticaria Control Test (UCT) is a valid and reliable tool to assess disease control in patients with CU and a score of ≥12 indicates well-controlled urticaria [1]. However, the most frequently utilized tool in clinical trials is the 7 days Urticaria Activity Score (UAS7) [1, 11]. It is also suitable for evaluation of disease activity by urticaria patients and their treating physicians. The UAS7 is based on the patient self-assessment of the two main urticaria signs and symptoms recorded once a day for 7 consecutive days:

  • wheals: 0 = none; 1 = mild (<20 wheals/24 hours); 2 = moderate (20–50 wheals/24 hours); 3 = intense (>50 wheals/24 hours or large confluent areas of wheals);

  • pruritus: 0 = none; 1 = mild (present but not annoying or troublesome); 2 = moderate (troublesome but does not interfere with normal daily activity or sleep); 3 = severe (severe pruritus, which is sufficiently troublesome to interfere with normal daily activity or sleep).

The sum of score is 0–6 for each day, and 0–42 for the UAS7 (0 = urticaria-free; 1–6 = well-controlled urticaria; 7–15 = mild activity; 16–27 = moderate activity; 28–42 = severe activity), respectively. Overall disease activity is best measured by advising patients to document 24-hour self-evaluation scores for several days.

For the patients affected by recurrent angioedema, alone or in addition to wheals, the last EAACI/GA2LEN/EDF/WAO guideline also suggests to use the Angioedema Activity Score (AAS) [1]. It consists of five items regarding the characteristics of angioedema to have occurred in previous 24 hours [11]. A score between 0 and 3 is assigned to every answer field. The question scores are added up to produce a daily score (0–15). Daily AAS can be summed to give 7-day (0–105), 4-week (0–420), and 12-week scores (0–1260) [12].

1.4 The Chronic Urticaria treatment guidelines

As first-line symptomatic treatment for urticaria, the EAACI/GA2LEN/EDF/WAO guideline suggests regular administration of second-generation, nonsedating, nonimpairing H1-receptor antihistamines due to their efficacy and good safety profile [1]. This class of drugs has a greater receptor specificity, lower penetration of the blood–brain barrier, and less likely to cause drowsiness or psychomotor impairment in comparison to the first-generation antihistamines.

In non-responders adult or paediatric patients, the second-line treatment is the up-dosing of the antihistamine by as much as 4-fold. For patients (aged 12 years and older) who have not responded to four-times the standard dose of second-generation H1-receptor antihistamine, omalizumab, a humanised monoclonal anti-IgE antibody, as add-on therapy is considered the third-line treatment. If there is no response to the omalizumab within 6 months, or if the condition is intolerable, the fourth-line treatment is the prescription of cyclosporine A (CsA), which inhibits the production of IL-2, IL-3, IL-4, and TNF-α in lymphocytes and the IgE-mediated release of histamine from mast cells. High doses of CsA and long duration treatment are associated with adverse events such as abdominal pain, nausea, vomiting, paresthesia, headache, hirsutism, elevated serum creatinine, and hypertension; however, these side effects resolve after reducing dosage [13]. Nevertheless, CsA should be avoided in patients with chronic kidney disease or poorly controlled hypertension. CsA at the dose of 3–5 mg/kg/day has been shown in small, double-blind, randomised controlled trials to be effective in patients with CSU who do not adequately respond to antihistamines [14, 15]. During CsA treatment, given the significant side effects, the blood pressure, renal function, and serum CsA levels should be monitored regularly.

A simplified stepwise algorithm for the treatment of CSU adapted from the EAACI/GA2LEN/EDF/WAO guideline is summarised in Figure 2. At any moment, short courses of corticosteroids (e.g. prednisone 25 mg/daily) are admitted if symptoms are exacerbated or poorly controlled [1].

Figure 2.

Simplified stepwise algorithm for the treatment of urticaria adapted from the current EAACI/GA2LEN/EDF/WAO guideline.

1.5 The anthystamines limit in Chronic Spontaneous Urticaria

In the pre-omalizumab period, treating CSU patients was a real challenge for physicians due to the low rates of response to H1-antihistamines, which were the only approved medication and the mainstay of symptomatic treatment. Two meta-analysis including studies published between January 1990 and November 2014 revealed that 63.2% and 38.6% of patients remain symptomatic despite treatment with licensed dose and updosed H1-antihistamines, respectively [16]. Another study reported even lower response rates to standard dosage, with disease control in only 22% of patients [17].


2. The role of anti-IgE antibodies in Urticaria

The immune system is a network of cells, tissues, and organs that work together to defend the body against attacks by foreign invaders such as bacteria, viruses, parasites, and fungi [18]. The host uses both innate and adaptive mechanisms to detect and eliminate pathogenic microbes, and both of these mechanisms include self-nonself discrimination. Immunoglobulins (Ig), also known as antibodies, are glycoproteins produced by white blood cells that are specific for an antigen (e.g., bacteria, viruses, parasites, or fungi), aiding its destruction by a cascade of downstream pathways. There are five primary classes of Igs (IgG, IgM, IgA, IgD and IgE), which differ in their biological features, structure, target specificity, and distribution [19]. Among them, IgE are involved in allergic reactions with a type I autoimmune mechanism.

2.1 IgE

It is believed that IgE have evolved to protect humans from helminth infections, which are one of the major threats to human life. IgE molecules exist in a monomeric form consisting of two heavy and two light chains and are the most important participants in an allergic reaction [20]. When a foreign substance, called allergen, enters our body, a person with an inherited predisposition to this substance will begin to develop a specific type of IgE, which will evoke a cascade of reactions aimed to eliminating this allergen. IgE are present in serum at very low concentration (∼50–200 ng/mL in a normal individual) and have a very short half-life (1–2 days). However, tissue-resident IgE may persist for several days (approximate half-life of 2 weeks in the skin) [21, 22]. This may be due to the extremely high affinity of IgE for the IgE Fc receptor (FcεRI) and in particular its slow dissociation from this receptor, resulting in re-binding of the dissociated IgE to its receptors, and restricted diffusion away from the tissue within which it resides [23].

There are two structurally and functionally distinct receptors that bind with the Fc epsilon (Fcε) region of IgE: the high affinity FcεRI and the lower affinity CD23 FcεRII [24, 25]. Through their Fc portions, IgE molecules bind to the Fc receptors present on the surface of mast cells and basophils. The cross-linking of such membrane-bound IgE antibodies by multivalent antigens triggers the release of chemically active substances, such as histamine, leukotrienes, prostaglandins, and chemotactic factors, from the cells. These substances initiate allergic and inflammatory reactions and serve as a chemoattractant for other cells [26].

2.2 Anti-IgE antibodies as Chronic Urticaria treatment: why?

This is the first question claimed by the scientific community, since IgE are involved in allergic reactions and CU is not known as an allergic reaction. Before answering this question, we should know the mechanism of action of omalizumab in CSU. Omalizumab has been effective in the treatment of urticaria, believed to have an autoimmune origin, and in cases where the etiology is unknown [27].

There are several hypotheses regarding the mechanism of action of omalizumab in CSU patients. One of them is based on the fact that the density of IgE receptors on the surface of mast cells and basophils is proportional to individual patient’s plasma IgE levels [28, 29]. It is hypothesized that omalizumab, by lowering free IgE levels in the blood and subsequently in the skin, may lead to down-regulation of a large percentage of surface IgE receptors, thereby decreasing downstream signaling via the FcεRI receptor pathway [30, 31]. Cell activation would then be diminished, and subsequent inflammatory processes, as complement activation and cellular infiltration, would be suppressed as well. As a consequence, the frequency and severity of symptoms of CSU would be lessened [28, 30, 31].

Another hypothesis is that omalizumab reduces the levels of circulating IgE, leading to a rapid and non-specific desensitization of cutaneous mast cells [32]. Subsequent effects, such as down-regulation of IgE receptor, may help to sustain the response. Serrano-Candelas et al. demonstrated comparable actions of omalizumab on mast cells and basophils while investigating the in vitro mechanism of action of omalizumab on these cells [33].

In a review by Kaplan et al. new insights into the potential mechanisms of action contributing to the efficacy of omalizumab in CIndU/CSU have been suggested based on both clinical and in vitro studies [30]:

  • omalizumab lowers IgE levels and down-regulates IgE receptors;

  • reduces mast-cell releasability;

  • decreases available FcεRI more slowly on mast cells than on basophils;

  • reduces IgE+/FcεRI+ cells by ∼12 weeks;

  • reverses basopenia and improves basophil IgE receptor function;

  • reduces the activity of intrinsically “abnormal” IgE;

  • decreases the activity of IgG autoantibodies against FcεRI and IgE;

  • reduces the activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified;

  • decreases in vitro coagulation abnormalities associated with disease activity.

Deza et al. investigated the effect of omalizumab on the basophil expression of FcεRI receptor in a cohort of patients with active CSU [34]. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks (p < 0.0001), which was maintained throughout the total duration of the treatment.

In a study by Asero et al., omalizumab responders showed a dramatic decrease of D-dimer plasma levels after the first administration of the drug (p = 0.003), suggesting a possible effect of omalizumab on coagulation activation and fibrin degradation [32].

However, none of these theories fully account for the pattern of symptom improvement seen with omalizumab therapy. Therefore, additional research is warranted to further explain the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIndU/CSU.

2.3 The Chronic Spontaneous Urticaria main endotypes

CSU is a mast cell-driven disease. The initial event in the development of skin changes, such as sensory nerve stimulation, vasodilation and extravasation, as well as the recruitment of basophils, eosinophils, and T cells, which lead to whealing, itch, and angioedema is attributed to the degranulation of skin mast cells.

Two groups of mast cell degranulation signals have been so far identified and characterized in CSU pathogenesis: IgE autoantibodies to autoallergens and IgG autoantibodies that target activating mast cell receptors [30]. Therefore, it is now clear that there are at least 2 distinct pathways, type I and type IIb autoimmunity, that contribute to the pathogenesis of this complex disease [35]. In type I hypersensitivity to self, also called autoallergy, antigens crosslink the IgE on mast cells and basophils to cause release of vasoactive mediators, while in type IIb hypersensitivity antibodies, usually IgG, bind to antigen on a target cell.

About twenty years ago, the demonstration of IgE autoantibodies against the thyroid microsomal antigen thyroperoxidase in the serum of a CSU patient, identified a possible role of type I autoimmunity in the pathogenesis of urticaria [36]. Many studies have further characterized the prevalence and pathogenic relevance of type I autoimmunity in CSU. In particular, CSU patients were found to express more than 2-fold higher IgE-anti-thyroperoxidase serum levels as compared to healthy control subjects (p < 0.001) [37].

Kolkhir et al. systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice-versa, finding a positive correlation between CSU and elevated levels of IgG antithyroid autoantibodies with the studies reporting rates consisted in 10% [38]. Levels of IgG against thyroid peroxidase resulted more often elevated in CSU than those of other IgG antithyroid autoantibodies (strong evidence). Moreover, CSU patients exhibited significantly higher levels of IgG antithyroid autoantibodies (strong evidence) and IgE anti-thyroperoxidase (weak evidence) than controls.

However, IgE autoantibodies directed to a large assortment of autoantigens beyond thyroperoxidase are expressed in the skin of CSU patients as thyroglobulin, tissue factor, and interleukin (IL)-24 [39, 40]. Hatada et al. found that the anti-dsDNA IgE levels were significantly higher in patients with CU than in normal subjects, while no differences in the anti-dsDNA IgG levels were observed [41]. Furthermore, most of the studies confirm that IgE autoantibodies should be responsible for the increased total IgE levels in CSU patients in which, differently to the control subjects, most of the IgE was found to be directed against autoantibodies.

A type IIb hypersensitivity mechanism in which IgG autoantibodies against IgE were involved, was first described in CSU in 1988 [42]. Few years later, IgG autoantibodies directed to FcεRI, the high-affinity receptor for IgE on masthocytes and basophils, were also identified [42]. Grattan et al. introduced the Autologous Serum Skin Test (ASST) in CSU patients, consisting in eliciting with an intradermal injection of their own serum a wheal and flare response [43]. A positive reaction in the ASST confirm the presence of these autoantibodies.

CSU driving by type IIb autoimmune mechanisms is further supported by the basophil activation test [44]. The serum of a subpopulation of CSU patients stimulates heterologous basophils and this activity is due to the presence of autoantibodies against FcεRI as well as in positive ASST responses.

The two endotypes play a key role in inducing different phenotipe of the same disease: type I (autoreactive) and type IIb (autoimmune) CSU patients differ in some features, laboratory markers, and rates and speed of response to treatment [45]. In particular, type IIb autoimmune CSU patients have been suggested to have higher disease activity and longer disease duration as well as higher rates of autoimmune comorbidity. Basopenia and eosinopenia may also be more common.

A higher proportion of patients receiving omalizumab 300 mg achieved response as early as week 4 (early responders) when compared with placebo [46]. This is in line with type I autoimmune/autoreactive mechanism: anti-IgE rapidly binds free IgE, including IgE against autoantigens, and IgE/anti-IgE complexes bind autoallergens preventing mast cell degranulation. CSU patients that take more than a month (late responders) to respond to omalizumab, probably underwent a type IIb autoimmunity, where the reduction of free IgE results in the slow loss of membrane-bound FcεRI from skin mast cells [46].

New endotypes of CSU have been proposed in addiction by recent reports, suggesting a key role of the coagulation pathway factors, ligands of the Mas-related G protein–coupled receptor X2, basophils, and other signals in the pathogenesis of CSU [47, 48]. Moreover, other research to characterize better the role and the relevance of type I and type IIb autoimmunity in CSU and to support the existence of distinct and separate endotypes, are still in progress.

In contrast to CSU, autoimmunity in CIndU has not yet been described.


3. Omalizumab in Urticaria

Omalizumab is a recombinant deoxyribonucleic acid-derived humanized monoclonal antibody manufactured from a mammalian cell line, that selectively binds to IgE. The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to free IgE, preventing its interaction with FcεRI (Table 1). It has been firstly indicated for adults and children (6 years of age and above) with moderate to severe persistent allergic asthma. Ten years later, omalizumab has been approved for the treatment of adults and adolescents (12 years of age and above) with CSU refractory to standard of care.

Anti-IgE AntibodiesMonoclonal antibody typeEquilibrium dissociation constant
PharmacokineticsMechanism of actionAdministrationAdverse events
(most frequent)
Omalizumab, Xolair®
(E25, IGE025)
Humanized IgG1/κ-light chain7 x 10−9 M
  • Maximum serum concentration within 7–8 days

  • Terminal elimination half-life ≈24 days

  • Steady state serum concentration at week 12

  • Attaches to the Cε3 domain of serum IgE, and thereby inhibits these IgE antibodies from binding to FcεRI high-affinity IgE receptor and CD23 receptor

  • No binding to receptor-bound IgE

  • Dissociates IgE from FcԑRI

  • 300 mg (two pre-filled syringes with 150 mg) subcutaneously

  • Every 4 weeks

  • Self-administration possible after four tolerated doses

  • Injection-site reactions

  • Upper respiratory infection

  • Headache

Humanized, IgG1/κ-light chain1.4 x 10−10 M
  • Maximum serum concentration within 4 days

  • Terminal elimination half-life ≈20–25 days

  • Steady state serum concentration at week 8–16

  • Inhibits IgE antibodies from binding to the FcεRI high-affinity IgE receptor

  • Interference with CD23 binding is debated

  • No binding to receptor-bound IgE, therefore no triggering of effector cells such as mast cells or basophils

  • 120 mg / 240 mg subcutaneously

  • Every 4 weeks

  • Final dosing regimen has yet to be defined

  • Injection-site reactions

  • Upper respiratory infection

  • Headache

UB-221Humanized IgG1Not publishedNot published
  • Attaches to the Cԑ3 domain of serum IgE, and thereby inhibits these IgE antibodies from binding to FcԑRI high-affinity IgE receptor

  • No inhibition of the interaction between IgE and CD23

  • No binding to FcԑRI-bound IgE, but binding to CD23-bound IgE, down-regulates IgE synthesis

  • 0.2 / 0.6 / 2 / 6 / 10 mg/kg intravenously

  • Single dose

  • Final dosing regimen has yet to be defined

Not published
QuilizumabHumanized, afucosylated, IgG1/κ-light chainNot published
  • Mean maximum observed serum concentrations of 34 ± 12.6 μg/mL at time of maximum observed serum concentration of 36.2 ± 3.5 days

  • Terminal elimination half-life ≈19–21 days

  • Binds membrane IgE at the M1-prime segment

  • No binding to free IgE

  • 300 mg subcutaneously

  • Every 4 weeks

  • Injection-site reactions

  • Arthralgia

  • Headache

Table 1.

Summary of the Anti-IgE Antibodies in Chronic Urticaria.

3.1 Phase II and III clinical studies

Omalizumab preliminary dose selection was provided by the phase II study MYSTIQUE, which evaluated the effect of the drug at different dosages [49]. While these results provided the preliminary data, pivotal dose selection was ultimately evaluated in two pivotal phase III efficacy trials (ASTERIA I and ASTERIA II) and was supplemented by data from the safety trial (GLACIAL) [12]. The GLACIAL study was adequately designed and controlled to provide efficacy information as well.

The MYSTIQUE study assessed the efficacy of three doses of omalizumab (75 mg, 300 mg, and 600 mg) as a single subcutaneous injection in patients with CSU refractory to H1-antihistamines (n = 90), which was followed by a 12-week observation period [49]. The primary endpoint was the mean change in UAS7 at Week 4. Patients in the omalizumab 300 mg and 600 mg groups had significantly greater improvements from baseline in the scores of UAS7 and weekly Itch Severity Score (ISS) compared with those in the placebo group. No additional benefits were observed in the 600 mg group over the 300 mg group. UAS7 scores with omalizumab 75 mg showed only marginal differences versus placebo [50]. The most frequently reported (≥5%) treatment-emergent adverse effects (AEs) during the treatment period were upper respiratory tract infection, headache, nasopharyngitis, and dysmenorrhea. Most AEs were mild to moderate in severity and were considered not related to the study drug [49].

In the XCUISITE study, omalizumab was administered according to the dosing table for allergic asthma using baseline IgE level and weight [50]. Treatment effects were analyzed by individual dose levels for the primary endpoint (change from baseline in UAS7 after 24 weeks) [51]. In the groups receiving omalizumab 300 mg and 150 mg every 4 weeks, a considerable improvement was observed in the UAS7 score compared with that in the placebo group, with a more pronounced effect observed with 300 mg [12]. Although the results of the study suggested a dose–response relationship, no conclusions were made regarding the comparative efficacy between the dose levels since the number of patients in each group was small (n = 6–7) and participants were not randomly assigned to the different dose levels [52]. In terms of safety in the XCUISITE study, the overall incidence of AEs during the treatment period was similar between the omalizumab and placebo groups. The most frequent AEs (>5%) in both groups were diarrhea, nasopharyngitis, and headache. No severe AEs or deaths related to omalizumab were reported [51].

The ASTERIA I, ASTERIA II, and GLACIAL studies were part of the omalizumab registration program in CSU. These were phase III, randomized, multi-center, double-blind, placebo-controlled studies that evaluated the efficacy and safety of omalizumab in patients with CSU [52, 53, 54]. Patients with CSU who remained symptomatic despite H1-antihistamine therapy were randomized to receive either placebo or subcutis omalizumab at the dosage of 75 mg, 150 mg, or 300 mg every 4 weeks for a total of 24 weeks in ASTERIA I (n = 319) and 12 weeks in ASTERIA II (n = 323) [52, 53]. The primary endpoint in both trials was the mean change in the ISS score at Week 12. Secondary was to evaluate the variation from baseline to Week 12 in the UAS7 score, weekly number of hives score, median time to minimally important difference in the ISS, weekly size of the largest hive score, proportion of patients with UAS7 ≤ 6, change in the Dermatology Life Quality Index score, proportion of patients with UAS7 = 0, and proportion of angioedema-free days from Week 4 to Week 12.

Instead, GLACIAL (n = 336) primarily evaluated the safety of omalizumab in patients with CSU who remained symptomatic despite treatment with H1-antihistamines (at up to four times the approved dose) plus H2-antihistamines and/or leukotriene receptor antagonists [51], according to the EAACI/GA2LEN/EDF/WAO urticaria guideline at that time [1]. In this study, patients were randomized 3:1 to receive either subcutaneous omalizumab 300 mg every 4 weeks or placebo for 24 weeks.

In all three studies, the treatment period was followed by a 16-week observation period during which no treatment was given [52]. Overall, no new safety issues were identified in the CSU clinical program [51]. No deaths occurred during either trial. The pivotal efficacy trials demonstrated a consistent dose-dependent treatment effect for the evaluated endpoints [49].

Anyway the licensed dosage for omalizumab for refractory CSU, with or without angioedema, in Europe is 300 mg every 4 weeks, independent of patient body weight, body mass index or serum IgE level, while in the USA this is either 150 or 300 mg [12, 52]. Instead, only the dosage of 300 mg every 4 weeks has been proven to be effective in case of angioedema. Currently, the licensed dosage in Italy is 300 mg every 4 weeks over a 6-month period, and in the case of disease recurrence, a minimum of 8 weeks suspension from omalizumab is mandatory, and then it can be prescribed again for a further 5 months only [12]. This schedule (6 months treatment, 8 weeks suspension, and 5 months therapy) can be repeated for eventual relapses; however, this de novo treatment is considered off-label.

To date, there are no licensed treatment options for CIndU and the recommended dosage with omalizumab is similar to CSU.

3.2 Omalizumab: real-life evidences

In clinical settings, the treatment of refractory CSU with omalizumab has been shown to be similar to, or in some cases even better than, those reported by the pivotal randomized controlled trials [12, 55, 56, 57, 58, 59, 60, 61].

The retrospective analysis of the three pivotal studies (ASTERIA I, ASTERIA II, and GLACIAL) put first in evidence that some CSU patients respond to treatment more quickly than others and for this reason two different categories were identified: “fast responders” for those who respond within 4–6 weeks and “slow responders” for whom obtain a response more gradually (from 12 to 16 weeks) [12]. However, “slow responders” may still respond even after 24 weeks, while some “fast responders” may obtain a response to treatment within 1 week, suggesting that the response patterns of patients to omalizumab may be due to the different pathomechanisms of the disease. These two different patterns of response have been soon confirmed by real-life experiences [12, 61, 62, 63]. In addition, the clinical assessment of CSU activity was not always uniform in all studies and different patient-reported outcome measures are used, either alone or in combination, to assess disease activity and guide the assessment of treatment efficacy.

Real-world studies have shown a response to treatment in 48–80% cases, while 7–14% are non-responders and 8–50% relapse after drug discontinuation [12, 55, 56, 57, 58, 59, 60, 61], supporting the efficacy and safety of omalizumab in CSU patients with an inadequate response to H1-antihistamines. These studies add precious information for the clinical management of CSU, but often present a relatively small sample size population and sometimes include different doses and administration timing of omalizumab. In particular, real-world studies demonstrated that omalizumab administration reduces the use of other CIndU/CSU-related medications. A recent large real-world retrospective study including 1546 patients with CIndU/CSU treated with omalizumab revealed that the majority started with a dosage of 300 mg and received the drug for an average of 9 months without dosing titration up or down [64]. Moreover, the use of other medications, such as corticosteroids and antidepressants, was consistently decreasing during the follow-up period, from 72.8% over the first 3 months to 58.5% over the last 3 months.

Additionally, real-life experiences have confirmed that there are different patient profiles according to omalizumab response [63, 65, 66]:

  • patients typically show a response to treatment within the first 4–8 weeks (often within 1 week);

  • patients initially non-responders can obtain a significant reduction in disease activity and even achieve “good control” (UAS7 ≤ 6) or “complete control” (UAS7 = 0) if the treatment is continued for up to 24 weeks.

Other different strategies mainly involve either modification of the omalizumab dose or a change in the treatment interval. Dose increases or reductions, if the complete CU symptoms control is achieved, should be stepwise [63].

Data on the response rate to omalizumab is available from meta-analyses and real-world evidence, but not all of them have assessed the time to response and, due to the different dosages and treatment durations, it is difficult to draw a common conclusion from these studies [32, 46, 49, 50, 53, 56, 57, 66, 67, 68, 69, 70, 71, 72, 73, 74]. Consequently, several parameters have been suggested to potentially predict treatment response, or possible treatment relapse. Some studies have been focused on different baseline clinical and laboratory parameters in order to identify the predictors of response to omalizumab in CSU patients. Asero et al. found that high levels of D-dimer seems to be a marker of response to treatment [32], but more recently the same authors and other studies indicate D-dimer only as a activity/severity marker in CSU patients and its plasma levels are reduced by omalizumab both in patients with and without angioedema at baseline [75]. Instead, many studies have shown that total IgE levels can be a marker of response to omalizumab [76]. Marzano et al. recently confirmed IgE basal levels as a reliable biomarker predicting response to treatment in CSU patients, while they did not support the usefulness of D-dimer [62]. In a single-center study on 47 CSU patients the baseline basophil FcεRI expression was found to be a potential immunological predictor of good and fast response to omalizumab (100% sensitivity and 73.2% specificity) [34].

The analysis of omalizumab responders in a prospective study of 64 patients showed that most basophil histamine release assay (BHRA)-positive patients responded only after the second injection, with a median time to response of 29 days, whereas BHRA-negative patients had a median time to response of only 2 days [77].

In a retrospective study of 41 antihistamine-refractory CU patients, the lack of basophil CD203c-upregulating activity in their serum correlated negatively with a clinical respond to omalizumab [78]. In detail, a significant association was found between the response and CD203c-upregulating activity, autoimmune phenotype, low IgE levels, and high eosinophil count levels.

Greater number of prior medications was associated with a lack of response to omalizumab in a study of 52 patients with severe CU, whereas the presence of anaphylaxis, angioedema, dermatographism, steroid use, and disease duration were not [79].

Furthermore, CSU duration before omalizumab and baseline UAS7 may be considered a negative markers of response and high relapse risk [62]. Although the response to omalizumab should not be dose dependent in CSU, real-life settings have shown that body mass index could influence the performance of the drug [17].

In a cohort of 154 patients the following factors were described as possible predictors of a favourable response to omalizumab [80]:

  • diagnosis of CSU vs. CIndU;

  • no prior treatment with immunosuppressant drugs;

  • older age;

  • shorter duration of symptoms;

  • absence of angioedema;

  • negative histamine release test.

Over 85% of patients who present these characteristics achieved a complete respond to treatment.

In relation to the dosing, the proportion of patients who showed complete response to omalizumab 150 mg ranged from 15–22% in clinical trials and from 36–79% in real-world studies. Regarding omalizumab 300 mg, the proportion of complete responders ranged from 34–44% in clinical trials and from 40% to 84.6% in real-life settings. However, not all real-world studies provided information on treatment duration. In few real-world studies where patients have received either/both omalizumab 150 mg and 300 mg, the complete response was observed in 47–83%. In addition, a complete response was achieved as early as the day after the administration of the first dose or within 5 months [66, 67, 68, 69, 70, 71, 72, 73, 74].

Real-world settings support that repeated treatment cycles should be required in several CSU patients [12, 70, 74, 81, 82]. Regarding the retreatment, omalizumab seems to be highly efficient in relapsed patients who previously had responded well [74]. An Italian retrospective clinical analysis revealed that the second cycle treatment with omalizumab is effective more quickly compared to the first cycle response [12]. Based on current international guidelines, omalizumab labelling information and experience in clinical practice, an Italian group provided treatment recommendations regarding the use of omalizumab in patients with CSU concluding that repeated cycles or extended treatment may be necessary in patients with disease relapse or late treatment response [81]. These authors suggested to continue the treatment when patients have a UAS7 > 6 and/or UCT < 12.

Among responders, after discontinuation of omalizumab the treatment can be resumed at a later stage with the same degree of symptom control [82].

All the real-world studies underlined the high safety prophile of omalizumab also in continuous and long-term administration. Finally, in a meta-analysis of 67 published reports, benefits and safety of omalizumab in the real-world treatment of CSU have met or exceeded results achieved in clinical trials [83].

3.3 Omalizumab performances optimization in clinical practice

Current evidence indicates that CSU usually last from 3 to 12 months, but patients may be affected for more than 1 year (sometimes even more than 5 years) [84]. However, recommendations regarding treatment duration and re-treatment after symptoms return are lacking. Nevertheless, the primary results of the OPTIMA study have shown that approximately 88% of patients who relapsed after being previously well-controlled with omalizumab, regain symptom control upon re-treatment within 3 months [85]. Similarly, phase IV XTEND-CIU study and few real-world studies have shown re-treatment to be effective in CSU patients who had previously responded to omalizumab but who relapsed after treatment withdrawal [4, 86]. To date, there are limited data comparing the therapeutic effect of omalizumab for patients with CSU, CIndU, and CSU plus CIndU. A recent chinese study revealed that omalizumab is highly effective and safe in 138 patients with difficult-to-treat CSU, CIndU, or both [87]. Among the CU patients enrolled, 87% responded to omalizumab therapy and those with higher baseline total IgE levels and longer disease durations showed more likely to experience rapid relapse after discontinuation of the drug.

Many other important questions regarding the use of omalizumab remain to be answered in order to optimize treatment management and patient outcomes. In particular, further investigations regarding predictors of good outcome, optimal dose, and dosing intervals based on treatment response to omalizumab in CSU are needed. A personalized therapeutic algorithm according to the patient clinical and bio-markers, modulated on the dose–response pattern, should facilitate the clinical management of omalizumab and help clinicians to determine the most appropriate therapeutic strategy for CSU. Future research is, therefore, required to evaluate the role of omalizumab in the various subtypes of CU as well as to establish standardized protocols for dosing and monitoring adverse effects of long-term therapy.


4. Ligelizumab (QGE031)

Even though omalizumab has been changing the management of CU, there is still a need for new targets and new biologics targeting new pathways in the management of the disease, which should provide long-lasting remission, be administered orally and cheaper. Among the CSU treatments that are still under clinical trials, there is anothers anti-IgE drug called ligelizumab (QGE031), which has been developed with the intention of overcoming some of the limitations associated with omalizumab [88].

4.1 Ligelizumab: what is it and how does it work in Chronic Spontaneous Urticaria

Ligelizumab, a next-generation high-affinity fully human monoclonal IgG anti-IgE antibody, demonstrated dose- and time-dependent suppression of free IgE, basophil FcεRI and basophil surface IgE superior in extent (free IgE and surface IgE) and duration to omalizumab (Table 1) [89, 90]. Ligelizumab recognizes a distinct IgE epitope only partially overlapping with that of omalizumab, interacting across the IgE-Fc dimer and favors the recognition of IgE in an open conformation different from its FcεRI- or CD23-bound conformations. Moreover, it binds IgE with significantly higher affinity (almost 50-fold higher) than omalizumab and shows a correspondingly enhanced inhibition of IgE binding to FcεRI and basophil activation. However, ligelizumab is inferior to omalizumab in preventing IgE binding to CD23. Structural analysis indicates that differences in the ligelizumab epitope and spatial orientation on IgE contribute to this differential inhibition [91].

Indeed, ligelizumab and omalizumab recognize distinct binding epitopes in the IgE Cε3 domain, showing some overlap but also different sensitivities to IgE conformation. On one side, the increased affinity of ligelizumab for IgE is superior than omalizumab regarding neutralization of free serum IgE, on the other side the additional mode of action for ligelizumab through the inhibition of IgE production may provide additional therapeutic benefit. Indeed, ligelizumab is more efficient in suppressing FcεRI-dependent allergic reactions in an in vivo model, while omalizumab may have advantages in blocking antigen presentation and transport processes that are dependent on IgE:CD23 interactions [92, 93].

4.2 Ligelizumab clinical studies

Currently, ligelizumab is being developed solely for the treatment of CSU. Phase IIb randomized controlled trial (NCT02477332) in CSU (CQGE031C2201) results demonstrated ligelizumab to be efficacious at 72 mg and 240 mg dosage, showing superiority over omalizumab and a comparable good safety profile [94]. The subsequent extension study (NCT02649218) in CSU (CQGE031C2201E1) proved the efficacy and safety of the ligelizumab at the dose of 240 mg every 4 weeks for a 1-year period, achiving more prolonged symptom control compared to the core study [95, 96].

4.2.1 CQGE031C2201

This was a 20-weeks multi-center, randomized, double-blind, placebo- and active controlled phase IIb dose-range finding study in subjects with CSU inadequately controlled [94]. CSU patients included in the study had to have a moderate-to-severe CSU defined as UAS7 of at least 16, 7 days hives severity score (HSS7) of at least 8, and in-clinic UAS of at least 4 (range 1 to 6) on at least one of the screening visit days. Exclusion criteria were represented by a previous exposure to omalizumab or ligelizumab, any other skin disease that is associated with chronic itching that might confound the trial evaluations and results, and a clearly defined underlying cause of CU other than CSU (e.g., inducible urticaria).

Subjects were randomized into 1 of 6 parallel treatment arms at a ratio of 1:2:2:2:1:1 (subcutaneous injections every 4 weeks of ligelizumab 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, a single dose of ligelizumab 120 mg followed by placebo or placebo) for the 20-week treatment period. The single 120 mg dose of ligelizumab was used to gain blinded wash-out information in relation to return of symptoms.

During the screening, treatment, and follow-up periods, nonsedating H1-antihistamines were used as rescue medication. Moreover, as background medication, this trial required concurrent use of H1-antihistamines at locally approved doses or at increased doses up to four times alone or in combination with H2-antihistamines or leukotriene-receptor antagonists (montelukast, zafirlukast, or pranlukast), according to the EAACI/GA2LEN/EDF/WAO urticaria guideline at that time [1].

Primary end-point was the achievement of complete hives response (HSS7 = 0) at week 12 (four weeks after the last injection), similar to phase III trials of omalizumab. Among 574 patients screened, 382 were included and 338 completed the treatment phase. The mean age ± SD of the study population was 43.3 ± 12.5 years (range 18 to 75 years) and 75% of subjects were female. Mean time since diagnosis of CSU was 4.3 ± 6.0 years. Median IgE levels at baseline was 87.2 IU/ml (range 0 to 14100).

With ligelizumab the main objective of the trial was achieved, showing a dose–response relationship with respect to the achievement of a HSS7 of 0 at week 12. The relationship resulted in a plateau starting close to the 72 mg dose of ligelizumab, while no further improvement in response was noted with the dosage of 240 mg.

At week 12, complete hive response was achieved in 30%, 51%, and 42% of patients treated with 24 mg, 72 mg, and 240 mg ligelizumab, respectively. Instead, a HSS7 of 0 was achieved only in 26% of patients with omalizumab and in none of those in the placebo group. The 7 days itch severity score (ISS7) showed a pattern similar to that seen with the hives-severity score. At week 12, UAS7 of 0 was achieved in 30%, 44%, and 40% of patients treated with ligelizumab 24 mg, 72 mg, and 240 mg, respectively, in comparison to 26% with omalizumab and none with placebo. Considering the scores (ISS7, UAS7, and HSS7) achieved, ligelizumab demonstrated superiority not only over placebo but also over omalizumab. In addition to hives and itch the AAS decreased to −21.1, −37.6, and − 27.3 among patients treated with 24 mg, 72 mg, and 240 mg ligelizumab, respectively, in comparison to −23.1 in patients with omalizumab and − 23.6 in the placebo group.

At week 4, the effect of the single 120 mg ligelizumab dose was similar to that seen with 72 mg and 240 mg and lasted until week 8. In contrast, a partial relapse of symptoms was noted with the 72 mg ligelizumab toward the end of the administration interval of four weeks. These data gave evidence that a dose higher than 72 mg ligelizumab could potentially provide enough drug effect throughout the administration interval of four weeks, minimizing symptom relapse. In support of this sustained treatment effect, the median time to loss of complete response in patients who had an UAS7 of 0 at the end of the treatment (week 20) was greatest in the patients treated with 240 mg of ligelizumab (10.5 weeks), while was similar in the groups that received 72 mg of ligelizumab or 300 mg of omalizumab (4 weeks).

Similar to omalizumab, the most frequent AEs were mild to moderate injection site reactions after subcutaneous administration (4% and 7% of patients treated with the 72 mg and 240 mg, respectively). All other minor AEs (mainly upper respiratory infections and headaches) showed no meaningful difference among the trial groups. Deaths, anaphylaxis or serious adverse events to ligelizumab have not been reported.

4.2.2 CQGE031C2201E1

Patients who completed CQGE031C2201 were eligible to be enrolled in this extension study at week 32 that confirmed the safety of the long-term (52 weeks) administration of the highest dose of ligelizumab (subcutaneous injections every 4 weeks of ligelizumab 240 mg) [95]. At week 52, 61.1% of patients achieved UAS7 ≤ 6 and, after stopping treatment, the median time of well-controlled disease was 28.0 weeks. These results implicate a longer treatment effect of ligelizumab compared to omalizumab [96].

4.2.3 CQGE031C1301

CQGE031C1301 represents a phase II multi-center, open-label study (NCT03907878) to investigate the safety/tolerability and efficacy of ligelizumab 120 mg every 4 weeks in adult Japanese patients with CSU inadequately controlled with H1-antihistamines. Currently, CQGE031C1301 is still ongoing.

4.2.4 Phase III ligelizumab study

Currently, two similar trials (PEARL 1 NCT03580356 and PEARL 2 NCT03580369) are ongoing to study the efficacy and safety of ligelizumab (72 mg or 120 mg every 4 weeks) in CSU patients who remain symptomatic despite standard of care treatment [97]. Both are 52-weeks multi-center, randomized, double-blind, placebo- and active controlled phase III trials and is planned to enroll about 1000 patients for each study.

In addition, a phase IIIb extension study is planned to investigate ligelizumab in adult and adolescent patients with CSU (NCT04210843) [98].

Results from these studies may confirm whether ligelizumab should become an alternative first-line treatment option in H1-antihistamine refractory CSU patients.


5. Anti-IgE antibodies in Chronic Spontaneous Urticaria special populations and drug interactions

To date, ligelizumab have not been investigated pregnant women, children, elderly, history of cancer, patients with renal or hepatic impairment, while only few studies were published regarding the use omalizumab in these special populations.

5.1 Pregnancy

Currently, omalizumab is not approved for use in pregnancy and there are only few case reports published in literature describing omalizumab as an effective and safe therapy for urticaria in pregnant women [99, 100, 101, 102].

The EXPECT study examined 250 women with with moderate-to-severe asthma exposed to omalizumab during pregnancy [102]. Each enrolled patient received at least one dose of omalizumab during pregnancy up to 8 weeks prior to conception. This study compared EXPECT outcomes with those from a disease-matched external population of pregnant women with moderate-to-severe asthma not treated with omalizumab. No significant difference in spontaneous abortions, major congenital anomalies, prematurity, or low birth weight was observed among pregnant women exposed to omalizumab compared with the disease-matched unexposed cohort. However, given the observational nature of this registry, an absence of increased risk with omalizumab cannot be definitively established. Therefore, omalizumab might be considered in pregnant women, but to date its use during pregnancy is not recommended by any accepted international or national guideline. Randomized controlled trials should be conducted on omalizumab during pregnancy before complete reassurance of the drug is established.

5.2 Children

Randomized controlled trials using omalizumab in urticaria included only a small number of 39 adolescent patients (aged ≥12 years) [103]. Passanisi et al. reported a case series of six children (66.7% males) with a mean age of 14.7 years (range 11–16 years) treated with at least one 6-months course of omalizumab [103]. The average follow-up period was 13 ± 6 months and only one patient was no responder, while three patients needed a second course of treatment. This study demonstrated that omalizumab is effective and safe as treatment option for CSU unresponsive adolescent patients. Moreover, Passanisi et al. summarized in his study the 12 previously published case reports. Applied omalizumab doses ranged from 75 mg every 4 weeks to 300 mg every 2 weeks for a period of up to 12 months, but most patients received the standard dose of 300 mg every 4 weeks.

Recently, a retrospective multi-center case series reported the use of omalizumab in 19 children (6 to 16.9 years old) with recalcitrant CSU [104]. Sixteen (84%) responded to omalizumab, although two became non-responsive after 6–12 months of therapy, while three patients (16%) were resistant to treatment, achieving remission through fourth-line (Cyclosporine A) or other therapies. This study stated that children with recalcitrant CSU, even those <12 years old, respond well to standard-dose of omalizumab at rates similar to adults. Future prospective randomized clinical trials of omalizumab and other anti-IgE therapies in children are needed.

5.3 Elderly (65 Years and Older)

Whilst the randomized clinical trials had an upper age limit of 75 years, the mean age of all included CSU patients was within the range of 40–45 years. Therefore, limited data are now available on the use of anti-IgE antibodies in patients older than 65 years, but there is no evidence that elderly patients require a different dose from younger adult patients. A recent Italian real-life experience on 32 patients ≥65 years of age found that omalizumab is a well-tolerated and effective therapy for elderly patients with nonsedating H1-antihistamine-refractory CSU [105].

5.4 History of cancer

To date, there are only few reports of effective and safe omalizumab treatment in patients with a history of previous cancer (e.g. with breast carcinoma, in-situ melanoma, thyroid carcinoma, laryngeal carcinoma, and pituitary adenoma) [106], while evidence in patients with active malignant disease is scarce. Very rarely CU can be caused by cancer and if so, resolves with its cure [107]. Therefore, current expert opinion suggested that omalizumab can be used in patients with cancer [108].

5.5 Patients with renal or hepatic impairment

As IgG monoclonal antibodies are mainly eliminated via intracellular catabolism, renal impairment or hepatic impairment is not expected to influence clearance of ligelizumab and omalizumab. No dedicated drug–drug interaction studies have been conducted so far. Hepatic metabolizing enzymes are not involved in monoclonal antibody elimination, consequentely no pharmacokinetic interactions with co-administered medicinal products are expected with the both medications.


6. The future in Chronic Spontaneous Urticaria: anti-IgE antibodies and beyond

In addition to drug repurposing as in anti-IL-4/13, IL-5, and IL-17 antibodies, novel targeted therapy options are currently undergoing clinical trials and will be available in the near future: other anti-IgE antibodies such as UB-221 and Quilizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab [5, 109]. New potential target molecules are going to be proposed as novel treatments and have been rapidly developing.

6.1 UB-221

UB-221 is a humanized IgG1 mAb (clone 8D6) that targets the Cε3 domain of IgE antibody and, unlike omalizumab, it can bind to IgE bound by CD23 (Table 1). UB-221 neutralizes IgE without activation of mast cells and basophils and was superior to omalizumab while targeting IgE by 3- to 8-folds in terms of pharmacologic effects. It is currently being investigated in two ongoing phase I trials for safety, tolerability, pharmacodynamics, and pharmacokinetics following a single dose (0.2, 0.6, 2, 6, 10 mg/kg UB-221 intravenously vs. placebo) in adult patients with CSU inadequately controlled with H1-antihistamines (NCT03632291 in Taiwan, and NCT04175704, location not provided).

6.2 Quilizumab

Quilizumab is a humanized, afucosylated, monoclonal IgG1 antibody, that binds membrane-bound IgE on B cells at the M1-prime segment, which is absent in soluble IgE (Table 1). In healthy volunteers and patients with allergic rhinitis or asthma, this anti-IgE antibody resulted able to reduce the total and specific IgE serum levels for at least 6 months after the last dose [110, 111]. This may implicate that quilizumab affects long-term IgE memory and bears the capacity for a sustained effect compared to omalizumab. Regarding quilizumab, there is no published evidence about its effect on angioedema and only one clinical trial is currently ongoing (NCT01987947) in CU. A previous randomized trial of quilizumab in adults with refractory CSU revealed that, although it reduced median serum IgE levels by approximately 30% over 20 weeks, it did not cause clinically relevant effects as assessed by ISS7 and UAS7 [112]. The study investigators hypothesized that the remaining serum IgE may be produced by long-lived IgE plasma cells that are not targeted by the drug due to their lack of membrane IgE.

6.3 Other possıble targets for treatment

Some other molecules participating in the pathogenesis of CSU might be important targets for treatment in the upcoming years.

  • In patients with CSU, C5a has been shown to enhance histamine release from mast cells upon activation of FcεRI through IgG autoantibodies [113]. Moreover, activation with C5a led to an increased basophil response in patients with CU compared to healthy controls [114]. These finding indicate a possible role for C5a in CSU and provide a basis for the evaluation of C5a inhibitors (IFX-1, eculizumab) in the treatment of CSU [115].

  • SHIP has been shown to be a key “gatekeeper” of mast cell degranulation. [116]. Indeed, SHIP acts as a negative regulator of degranulation by hydrolyzing phosphatidylinositol-3,4,5-trisphosphate, a second messenger generated in activated cells by phosphatidylinositol 3-kinase. SHIP-negative mast cells are more likely to degranulate following IgE binding. Instead, CD200R represents a novel and potent inhibitory receptor that can be targeted in vivo to regulate mast cell-dependent pathologies [117]. Considering their regulatory functions on mast cells, the use of SHIP and CD200R antibodies might be of interest in CSU.

  • Histamine H4 receptors (H4R) are expressed by hematopoietic cells including eosinophils, mast cells, neutrophils, and T cells. Activation of H4 receptors results in chemotaxis, cytokine production, immunomodulation, and inflammatory cell trafficking [118]. The use of H4R-antagonist called JNJ-7777120 has been associated with reduction of histamine-mediated scratching and Th2-induced inflammation in dermatitis [119]. Another H4R-antagonist, ZPL-3893787, improve inflammatory skin lesions in patients with atopic dermatitis compared to placebo [120]. The anti-inflammatory and anti-pruritic effects of H4R-antagonists might be of benefit in CSU treatment.

  • IL-31 is a pro-inflammatory cytokine mainly secreted by Th2 cells that exerts its effects through two receptors: IL-31 receptor A and oncostatin M receptor (OSMR) [121]. Increased expression of OSMR protein and histamine release were also shown in chronic autoimmune urticaria. In addition, OSMR gene silencing in mice led to a decrease in inflammatory cytokines and number of eosinophils [122]. These data indicate that IL-31 or OSMRβ inhibitors (e.g., nemolizumab, vixarelimab) might play an interesting role in the treatment of CSU.

  • Increased levels of IL-6, another pro-inflammatory cytokine, have been demonstrated in patients with CSU [123]. It was also correlated with disease severity, suggesting the role of systemic inflammation in CSU. Tocilizumab, an IL-6 monoclonal antibody, led to improvement in patients with Schnitzler syndrome, and might be of potential benefit for CSU treatment [124].

  • The increased expression of Mas-related gene X2, which is a receptor for histamine-releasing neuropeptides including substance P and vasoactive intestinal peptides, was demonstrated to be a possible therapeutic target in mast cells of patients with CSU [125].

  • The antagonists for neurokinin receptor-1 (e.g., aprepitant, tradipitant), which is the main cutaneous receptor for substance P, are under investigation for atopic dermatitis for their antipruritic effects and they might be of value for CSU as well [126].

  • The expression of thymic stromal lymphopoietin (TSLP), a promotor of Th2 response, was shown to be increased in patients with CSU, thus making the anti-TSLP monoclonal antibody, tezepelumab, a potential treatment option for CSU [127].

  • Calcium Release-Activated Calcium Modulator 1 (CRACM1/ORAI1) is a subtype of Ca2+ membrane channel, causing Ca2+ influx into the cells and mast cell degranulation [128]. Ca2+ is an essential element that regulates immune responses, especially in the development and function of T and B cells, and therefore ORAI1 is considered to participate in allergic diseases. Jie et al. have demonstrated that different single nucleotide polymorphisms in the ORAI1 gene are associated with an increased risk of CSU and better response to desloratadine [129]. Thus, targeting of ORAI1 via silencing RNAs might be of therapeutic value in CSU.


7. Conclusions

The introduction of anti-IgE antibodies in urticaria management has been representing a milestone in the treatment of H1-antihistamine refractory patients.

The results of the anti-IgE antibodies on CU in phase II and III randomised controlled trials [49, 50, 53, 54, 94, 112, 130, 131, 132, 133, 134, 135, 136, 137] were summarized in Table 2.

Name of the StudyPhaseIndicationPatients includedAnti-IgE antibodies dose every 4 weeksEfficacy on AngioedemaOutcome with anti-IgE antibodiesOutcome with placeboYear of publication [reference]
X-CUISITEIIChronic spontaneous urticaria°
(patients exhibit IgE against thyroperoxidase)
  • Omalizumab 75 to 375 mg according to baseline IgE and body weight

Not evaluated with scoreWeek 24
UAS7 = −17.8
DLQI = −6.3
CU-Q2oL = −21
Week 24
UAS7 = −7.9
DLQI = −1.5
CU-Q2oL = −2.3
MYSTIQUEIIChronic spontaneous urticaria°90
  • A single dose of omalizumab 75 mg

  • A single dose of omalizumab 300 mg

  • A single dose of omalizumab 600 mg

Week 4
  • Omalizumab 75 mg

UAS7 = −9.8
ISS7 = −4.5
HSS7 = −5.3
  • Omalizumab 300 mg

UAS7 = −19.9
ISS7 = −9.2
HSS7 = −10.7
  • Omalizumab 600 mg

    UAS7 = −14.6

    ISS7 = −6.5

HSS7 = −8.1
Week 4
UAS7 = −6.9
ISS7 = −3.5
HSS7 = −3.5
MoAIIChronic spontaneous urticaria°
(healthy controls included)
  • Omalizumab 300 mg

AEFDWeek 4 to 12
AEFD = 90.9
Week 12
UAS7 = −23.1
CUQ2oL = −39.2
DLQI = −10.2
Week 4 to 12
AEFD = 70.5
Week 12
UAS7 = −8.1
CUQ2oL = −5.7
DLQI = −3.1
X-ACTIIIChronic spontaneous urticaria°91
  • Omalizumab 300 mg

Week 0 to 28
AEBD = 14.6
MAEBD = 9 days
Week 28
UAS7 = −16.8
CUQ2oL = −30.9
DLQI = −10.5
AE-QoL = −41.4
MTFRAE = 56–63 days
Week 0 to 28
AEBD = 49.5
MAEBD = 30 days
Week 28
UAS7 = −6.5
CUQ2oL = −12.1
DLQI = −5.6
AE-QoL = −24.2
MTFRAE = <5 days
2016, 2018
[131, 132]
ASTERIA IIIIChronic spontaneous urticaria°319
  • Omalizumab 75 mg

  • Omalizumab 150 mg

  • Omalizumab 300 mg

AEFDWeek 4 to 12
  • Omalizumab 75 mg

    AEFD = 86.5

  • Omalizumab 150 mg

    AEFD = 89.6

  • Omalizumab 300 mg

    AEFD = 96.1

Week 12
  • Omalizumab 75 mg

UAS7 = −13.8
ISS7 = −6.5
HSS7 = −7.4
DLQI = −6.3
CU-Q2oL = −19.2
  • Omalizumab 150 mg

UAS7 = −14.4
ISS7 = −6.7
HSS7 = −7.8
DLQI = −8.0
CU-Q2oL = −23.1
  • Omalizumab 300 mg

    UAS7 = −20.8

    ISS7 = −9.4

HSS7 = −11.4
DLQI = −10.3
CU-Q2oL = −30.5
Week 24
  • Omalizumab 75 mg

UAS7 = −14.9
ISS7 = −7.0
HSS7 = −8.0
  • Omalizumab 150 mg

UAS7 = −14.2
ISS7 = −6.5
HSS7 = −7.8
  • Omalizumab 300 mg

    UAS7 = −22.1

    ISS7 = −9.8

    HSS7 = −12.3

Week 40(at the end of 16 weeks of follow-up)
  • Omalizumab 75 mg

DLQI = −7.0
  • Omalizumab 150 mg

DLQI = −5.2
  • Omalizumab 300 mg

DLQI = −4.9
Week 4 to 12
AEFD = 88.2
Week 12
UAS7 = −8.0
ISS7 = −3.6
HSS7 = −4.4
DLQI = −6.1
CU-Q2oL = −19.7
Week 24
UAS7 = −11.73
ISS7 = −5.4
HSS7 = −6.3
Week 40(at the end of 16 weeks of follow-up)
DLQI = −7.9
ASTERIA IIIIIChronic spontaneous urticaria°323
  • Omalizumab 75 mg

  • Omalizumab 150 mg

  • Omalizumab 300 mg

AEFDWeek 4 to 12
  • Omalizumab 75 mg

    AEFD = 93.5

  • Omalizumab 150 mg

    AEFD = 91.6

  • Omalizumab 300 mg

AEFD = 95.5
Week 12
  • Omalizumab 75 mg

UAS7 = −13.82
ISS7 = −5.9
HSS7 = −7.2
DLQI = −7.5
CU-Q2oL = −20.6
  • Omalizumab 150 mg

UAS7 = −17.9
ISS7 = −8.1
HSS7 = −9.8
DLQI = −8.3
CU-Q2oL = −27.0
  • Omalizumab 300 mg

    UAS7 = −21.7

    ISS7 = −9.8

    HSS7 = −12.0

    DLQI = −10.2

CU-Q2oL = −31.4
Week 4 to 12
AEFD = 89.2
Week 12
UAS7 = −10.4
ISS7 = −5.1
HSS7 = −5.2
DLQI = −6.1
CU-Q2oL = −17.7
GLACIALIIIChronic spontaneous urticaria*336
  • Omalizumab 300 mg

AEFDWeek 4 to 12
AEFD = 91.0
Week 12
UAS7 = −19.0
ISS7 = −8.6
HSS7 = −10.5
DLQI = −9.7
CU-Q2oL = −29.3
Week 4 to 12
AEFD = 88.1
Week 12
UAS7 = −8.5
ISS7 = −4.6
HSS7 = −4.5
DLQI = −5.1
CU-Q2oL = −16.3
POLARISIIIChronic spontaneous urticaria°218
  • Omalizumab 150 mg

  • Omalizumab 300 mg

Week 12
  • Omalizumab 150 mg

UAS7 = −18.8
ISS7 = −8.8
HSS7 = −10.0
DLQI = −7.2
  • Omalizumab 300 mg

    UAS7 = −22.4

    ISS7 = −10.2

    HSS7 = −12.2

    DLQI = −8.4

Week 12
UAS7 = −13.9
ISS7 = −6.5
HSS7 = −7.4
DLQI = −5.3
UFOIISymptomatic dermographism61
  • Omalizumab 150 mg

  • Omalizumab 300 mg

Week 10
  • Omalizumab 150 mg

    CFT = −1.8

    CR = 44%

  • Omalizumab 300 mg

    CFT = −2.0

    CR = 53%

Week 10
CFT = −0.6
CR = 11%
CUN-OMAL-UCOLIICholinergic urticaria§22
  • Omalizumab 300 mg

    (first 4 months blinded, followed by 8 months open-label)

Week 16
No difference in negative exercise challenge test rate compared to placebo
UCOL score = −28
CU-Q2oL = −7.6
VAS = −10
Week 48
Negative exercise challenge test: 31% Significant progressive improvement along time starting from week 16
Week 16
UCOL score = −16
CU-Q2oL = −6.5
VAS = −10
Week 48
Theoretical negative exercise challenge test: 11%
CUTEXIICold urticaria31
  • Omalizumab 150 mg

  • Omalizumab 300 mg

Week 10
  • Omalizumab 150 mg

    CTT = −10.6°C

    CR = 40%

  • Omalizumab 300 mg

    CTT = −10.4°C

    CR = 44%

Week 10
CTT = −0.3°C
CR = 0%
XOLUSIISolar urticaria10
  • Omalizumab 300 mg

Week 12
MUDi = 20%
DLQI <6 = 40%
VAS50 = 40%
Week 20
MUDi = 0%
DLQI <6 = 11%
VAS50 = 0%
No placebo arm; comparison to baseline2016
CQGE031C2201IIbChronic spontaneous urticaria*382
  • Ligelizumab 24 mg

  • Ligelizumab 72 mg

  • Ligelizumab 240 mg

  • Omalizumab 300 mg

AAS7Week 12
  • Ligelizumab 24 mg

UAS7 = −16.0
ISS7 = −7.0
HSS7 = −9.0
AAS7 = −20.0
  • Ligelizumab 72 mg

UAS7 = −27.0
ISS7 = −10.3
HSS7 = −16.5
AAS7 = −37.6
  • Ligelizumab 240 mg

UAS7 = −22.9
ISS7 = −10.0
HSS7 = −14.0
AAS7 = −29.9
  • Omalizumab 300 mg

UAS7 = −18.5
ISS7 = −8.8
HSS7 = −11.0
AAS7 = −25.0
Week 20
  • Ligelizumab 24 mg

UAS7 = −19.5
ISS7 = −7.5
HSS7 = −9.75
AAS7 = −22.6
  • Ligelizumab 72 mg

UAS7 = −26.5
ISS7 = −9.5
HSS7 = −15.5
AAS7 = −35.2
  • Ligelizumab 240 mg

UAS7 = −21.8
ISS7 = −9.0
HSS7 = −13.5
AAS7 = −27.3
  • Omalizumab 300 mg

UAS7 = −19.0
ISS7 = −8.0
HSS7 = −11.0
AAS7 = −23.1
Week 12
UAS7 = −13.0
ISS7 = −5.0
HSS7 = −7.5
AAS7 = −23.6
Week 20
UAS7 = −12.0
ISS7 = −5.5
HSS7 = −6.5
AAS7 = −24.4
QUAILIIbChronic spontaneous urticaria^32
  • Quilizumab 450 mg

Week 20
UAS7 = −2.0
ISS7 = −5.3
HSS7 = −0
Week 20
UAS7 = −11.0
ISS7 = −2.2
HSS7 = −3.5

Table 2.

Clinical Efficacy of Anti-IgE Antibodies in Phase II and III randomised controlled trials of Chronic Urticaria.

Inadequately controlled by H1-antihistamine at approved dose.

Inadequately controlled with a doubled dose of H1-antihistamine.

Inadequately controlled with H1-antihistamines at approved or increased doses alone or in combination with leukotriene receptor antagonists.

Inadequately controlled with H1-antihistamines at approved or increased doses alone or in combination with H2-antihistamines or leukotriene receptor antagonists.

Abbreviations:7 days Angioedema Severity Score, AAS7; 7 days Hives-Severity Score, HSS7; 7 days Itch Severity Score, ISS7; 7 days Urticaria Activity Score, UAS7; Angioedema Free Days, AEFD; Angioedema Burdened Days, AEBD; Angioedema Quality of Life, AE-QoL; Cholinergic Urticaria score, UCOL score; Chronic Urticaria Quality of Life, CU-Q2oL; critical friction threshold, CFT; complete response, CR; Dermatology Life Quality Index, DLQI; Median Angioedema Burdened Days, MAEBD; Median Time to First Recurrence of Angioedema after last injection of study drug, MTFRAE; >10-fold increase in minimal urticarial dose, MUDi; Visual Analogue Scale, VAS; 50% improvement from baseline measured on a visual analog scale, VAS50.

Omalizumab 300 mg every 4 weeks, as add-on therapy, has demonstrated effective and safe in most, but not all, patients with CSU and there is evidence that this holds true for angioedema and CIndU. However, additional studies, using registries, real life settings and controlled trials should investigate personalized dosages and administration intervals, based on e. g. body mass index, UAS7 results, and on the identification of biomarkers able to predict changes in disease activity in response to therapy, for the development of tailored treatment algorithms to be used in clinical practice.

Current data of ligelizumab, being the next-generation anti-IgE antibody that is one-step ahead in clinical trials, are very promising and it has the potential to be a valid alternative for CSU patients unresponsive to omalizumab. If the phase III trial program confirms the superiority of ligelizumab compared to omalizumab, there is hope that symptoms might be controlled in all patients with CSU.

There are no licensed treatment options for CIndU and, therefore, recommended treatment is similar to CSU. However, off-label use of omalizumab has shown to be less effective compared to in CSU. Results from randomized controlled trials of ligelizumab for CIndU seem to be highly encouraging.

It will be intersting to see whether next-generation anti-IgE therapies are effective in CSU, CIndU and angioedema. The mechanism of action of the various anti-IgE approaches should be further elucidated in order to optimize the treatment of CU patients and its better understanding might enable targeted therapy in the near future.



The chapter was funded by Novartis Farma S.p.A.


Conflict of interest

The authors declare that they have no competing interests.


Author contributions

All authors made substantive intellectual contributions to the published chapter, and each author listed on the publication has seen and approved the submission of the chapter.


Honorarium, grant, or other form of payment was not given to anyone of the authors to produce the chapter.


AASAngioedema Activity Score.
AE-QoLAngioedema Quality of Life.
AEsAdverse Effects.
ASSTAutologous Serum Skin Test.
AUAcute Urticaria.
BHRABasophil Histamine Release Assay.
CIndUChronic Inducible Urticaria.
CRACM1/ORAI1Calcium Release-Activated Calcium Modulator 1.
CsACyclosporine A.
CUChronic Urticaria.
CU-Q2oLChronic Urticaria Quality of Life.
CSUChronic Spontaneous Urticaria.
FcεRIIgE Fc receptor.
H4RHistamine H4 receptors.
HSS77 days Hives Severity Score.
ISSItch Severity Score.
ISS77 days Itch Severity Score.
OSMRoncostatin M receptor.
QoLQuality of Life.
TSLPThymic Stromal Lymphopoietin.
UASUrticaria Activity Score.
UAS77 days Urticaria Activity Score.
UCTUrticaria Control Test.


chapter PDF

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Patrizia Pepe and Victor Desmond Mandel (August 9th 2021). The Role of Anti-IgE Antibodies in Urticaria [Online First], IntechOpen, DOI: 10.5772/intechopen.97025. Available from:

chapter statistics

37total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us